On 21 April 2020, FDA Circular No. 2020-015 entitled “Interim Measures to Ensure Access to Vitamin Drug Products during the Coronavirus Disease 2019 (COVID-19) Pandemic” was issued. The said Circular provided interim guidelines for the registration and certification of vitamin products in response to the shortage of supplies in the market brought upon by the limited production and supplies due to the enhanced community quarantine (ECQ).
Due to the regular updates to the quarantine status of the different cities and municipalities, the provisions of this Circular may still deemed be applicable and necessary by the public’s interest.
In view of the foregoing, the provisions of FDA Circular No. 2020-015 shall be effective until 31 December 2020, subject for extension upon the review of this Office.
Attachment:-> FDA Circular No.2020-015-A